解析艰难梭菌毒素中和抗体的结构域特异性
艰难梭菌感染的病理效应主要归因于毒素A和B,毒素特异性抗体应答与无症状携带相关。研究通过毒素中和试验评估靶向TcdB多个结构域的人源单克隆抗体组合,发现针对所有主要毒素结构域的抗体组合比单抗体或针对一两个结构域的抗体组合具有更强的中和效力。用类毒素疫苗候选物免疫仓鼠诱导的血清抗体针对TcdA和TcdB的多个结构域,多克隆血清对高浓度毒素的中和活性优于等浓度单个单抗。
要点
- 靶向TcdB所有主要结构域的单抗组合中和效力优于单抗体或针对一两个结构域的抗体组合。
- 类毒素疫苗候选物免疫仓鼠可诱导针对TcdA和TcdB多个结构域的中和抗体。
- 多克隆血清对高浓度毒素的中和活性优于等浓度单个单抗。
核心结论
- 靶向多个毒素结构域的抗体疗法或预防措施可能具有潜在益处。
研究设计与样本
- 采用毒素中和试验评估靶向TcdB多个结构域的人源单克隆抗体组合,并用类毒素疫苗候选物免疫仓鼠评估血清抗体功能与结构域结合特异性。
主要发现
- 针对所有主要毒素结构域的单抗组合中和效力优于等浓度单个单抗或针对一两个结构域的单抗组合。
- 类毒素疫苗候选物免疫仓鼠诱导的血清抗体针对TcdA和TcdB的多个结构域。
- 多克隆血清在毒素中和试验中对高浓度毒素的活性优于等浓度单个单抗。
临床怎么用
- 抗体治疗或预防策略可考虑靶向艰难梭菌毒素的多个结构域以增强中和效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridium difficile infection (CDI) is the principal cause of nosocomial diarrhea and pseudomembranous colitis associated with antibiotic therapy. The pathological effects of CDI are primarily attributed to toxins A (TcdA) and B (TcdB). Adequate toxin-specific antibody responses are associated with asymptomatic carriage, whereas insufficient humoral responses are associated with recurrent CDI. While the data supporting the importance of anti-toxin antibodies are substantial, clarity about the toxin domain specificity of these antibodies is more limited. To investigate this matter, combinations of human mAbs targeting multiple domains of TcdB were assessed using toxin neutralization assays. These data revealed that a combination of mAbs specific to all major toxin domains had improved neutralizing potency when compared to equivalent concentrations of a single mAb or a combination of mAbs against one or two domains. The function and toxin domain binding specificity of serum antibodies elicited by immunization of hamsters with a toxoid vaccine candidate was also assessed. Immunization with a toxoid vaccine candidate provoked toxin neutralizing antibodies specific to multiple domains of both TcdA and TcdB. When assessed in a toxin neutralization assay, polyclonal sera displayed greater activity against elevated concentrations of toxins than equivalent concentrations of individual mAbs. These data suggest a potential benefit of any antibody based therapeutic or prophylactic treatment that targets multiple toxin domains.
引用
- Cole LE, Li L, Jetley U, et al. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies. Vaccine. 2019. PMID: 31122858. doi:10.1016/j.vaccine.2019.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。